Biotechnology
Trinity Biotech plc, a commercial stage biotechnology company focused on diabetes management solutions and human diagnostics, will report its financial results for the second quarter 2024 on Wednesday, August 14, 2024. This announcement comes as the company continues to expand its product offerings, including wearable biosensors, and enters the wearable
Biotechnology
On August 5, 2024, China Biotech Services Holdings Limited issued a statement announcing a Capital Injection Agreement between the Company, Hubei Weiyou, and Dynamic Healthcare. The agreement states that Hubei Weiyou will contribute up to RMB242,307,600 (approximately HK$261,692,208) to Pengbo (Hainan) to subscribe for 35%
Biotechnology
Nucleome Therapeutics, a leading biotechnology company spun out from Oxford University, will occupy a significant portion of the newly built Inventa building in Oxford's West End. This state-of-the-art complex is the first commercial science scheme delivered in the city's West End, strategically located within walking distance
Biotechnology
Duopharma Biotech Berhad, a Malaysian-based pharmaceutical company, has witnessed a significant change in its shareholding structure with the Employees Provident Fund Board (EPF) acquiring additional shares. EPF, a substantial shareholder, has increased its stake in the company through Citigroup Nominees (Tempatan) Sdn. Bhd., its nominee. This acquisition highlights the interest
Biotechnology industries
The biotechnology industry in Australia is crying out for tax breaks to encourage investors to back late-stage drug trials, with the industry's cash-strapped sector facing significant challenges in funding its operations. Leon Serry, an industry stalwart, has been lobbying the Federal Government for a 100% tax deduction for
Biotechnology industries
Oncolytics Biotech Inc., a Calgary-based biotechnology company focused on the development of oncolytic viruses as potential cancer therapeutics, will present a corporate overview at the Rodman & Renshaw 3rd Annual Global Healthcare Conference on May 16, 2006. Dr. Brad Thompson, President and CEO, will lead the presentation at 11:55
Biotechnology industries
GPC Biotech AG, a biopharmaceutical company, has announced the opening of a Phase 2 study of satraplatin, its lead drug candidate, in patients with metastatic breast cancer who have received no more than one prior chemotherapy treatment regimen. The study is being managed by US Oncology, a leading healthcare services
Biotechnology industries
Meditech Research Ltd (MTR), a biotechnology company focused on developing new cancer therapies, has made significant progress in its discussions with the U.S. Food and Drug Administration (FDA) regarding its lead product, HyCAMP. After a formal meeting with the FDA, Meditech has confirmed its intention to submit an investigational
Biotechnology industries
Genzyme Corp. announced a strong second quarter 2005, with revenue increasing 22% to $668.1 million from $549.6 million in the same quarter last year. The company's non-GAAP net income rose 46% to $149.0 million, and non-GAAP earnings per diluted share increased to $0.57 from
Biotechnology industries
HepaLife Technologies, Inc. (HPLF) has entered into an agreement with Fusion Capital Fund II, LLC to raise up to $15 million in equity financing. The agreement allows HPLF to sell newly issued stock to Fusion Capital in monthly installments of up to $500,000 over a period of up to
Biotechnology industries
Morphotek, Inc., a biotechnology company focused on developing optimized therapeutic antibodies, has strengthened its partnership with Baxter Healthcare Corporation by broadening their manufacturing supply agreement. This move will enable Morphotek to secure a steady supply of its lead compounds, including MORAb-003, which is currently in phase I clinical trials for
Biotechnology industries
Procyon Biopharma Inc. and IMI International Medical Innovations Inc. have expressed their shared excitement over the progress made in the study of ColorectAlert, a patented test for the early detection of colorectal cancer. The test involves analyzing a sample of rectal mucus taken during a routine doctor visit, which is
